NLS Collaboration

The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit public-private partnership in this space. The partnership plays a […]

Sigrid Therapeutics has entered into an agreement with Cencora aimed at accelerating the commercialization of its SiPore technology. SiPore21 is currently undergoing SHINE clinical trials as an innovative medical device designed for sustained blood sugar and weight control. Administered orally, SiPore21 utilizes a mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and […]

Novo Nordisk has entered into a collaboration and license agreement with the Swiss company EraCal Therapeutics. The two companies will develop and commercialize EraCal’s oral, small molecule program. The asset is believed to target a novel mechanism of action controlling appetite and body weight to treat obesity. Milestones of up to EUR 235 million Novo […]

Swedish pre-clinical biomarker assay company Offspring Biosciences and US spatial biology and biomarker analytics company Flagship Biosciences have announced a strategic partnership. The partnership aims to further advance precision drug development with a complete biomarker offering from discovery to companion diagnostics development, the companies state. “Together, Flagship Biosciences and Offspring Biosciences will provide a seamless […]

The company’s collaborative project with Vecura at Karolinska University Hospital and Uppsala University has been awarded SEK 850,000 from the Center for Advanced Medical Products (CAMP). The purpose of the project is to develop an automated production process of CAR T-cells (ELC-401) for use in clinical studies. The production process will be developed in a […]

Orion Corporation and Glykos Finland have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs). Under the agreement, Orion gains access to Glykos’ ADC technologies, initiating an ADC program with the potential for expansion into two additional programs in the future. Orion will be responsible for the target selection, research, […]